The Seven Types of Patients That Could Benefit from High Velocity Therapy
High Velocity Therapy delivered with Hi-VNI® Technology is mask-free noninvasive ventilation (NIV) for spontaneously breathing patients. It is a viable alternative to NiPPV and can relieve undifferentiated respiratory distress, including hypercapnia and hypoxemia. It is one user-friendly tool that could benefit a variety of patients from neonate to end-of-life.
Treating the Congested Patient with High Velocity Therapy
Whether it’s pneumonia, bronchiolitis, or other respiratory infections, secretion clearance is one of the keys to symptom relief. Rehydration of airway mucosa to promote mucociliary function helps with secretion clearance, and this can be effectively achieved by inhalation of heated, humidified gas.
Study Shows Clinicians Using Vapotherm® Oxygen Assist Module Prototype Significantly Better at Achieving Target SpO2 in NICU than Manual Titration
In November 2018, the Archives of Disease in Childhood: Fetal & Neonatal edition published the results of a prospective, two-center, order-randomized cross-over study performed at two NICUs in the UK, designed to evaluate the performance of Vapotherm’s® forthcoming Oxygen Assist Module (OAM) technology.
Rethinking Ventilation — Do you always need pressure?
The frequent-flyer COPDer comes into the hospital, dyspneic and tripoding and the respiratory therapist is readying the non-invasive positive pressure ventilation (NiPPV) — this is a frequent sight for clinicians admitting respiratory distress patients. NiPPV has been the gold standard treatment for patients with hypercapnia. It reduces the risks associated with mechanical ventilation while also being more tolerable for the patient.
Five Reasons Your Hospital Should Try High Velocity Therapy
High Velocity Nasal Insufflation (HVNI) is Mask-Free Noninvasive Ventilation pioneered by Vapotherm® for the treatment of undifferentiated respiratory distress in spontaneously breathing patients. Here are a few benefits that hospitals, clinicians, and their patients may experience with this breakthrough at the frontlines of respiratory care.
FDA Grants Vapotherm’s De Novo Request for New Category for Precision Flow Hi-VNI System
The U.S. Food and Drug Administration (FDA) granted Vapotherm’s request for a new category (QAV), and expanded indications for the latest version Precision Flow, the Precision Flow Hi-VNITM system. The indication now states this system may be used to augment breathing of spontaneously breathing patients suffering from respiratory distress in the acute setting.
What is Mask-Free NIV?
For patients in respiratory distress, non-invasive positive pressure ventilation (NiPPV) has been the first-line approach for decades. It’s a respected standard of care, but not all patients can tolerate this mask-based therapy.
How to Select Clinically Effective Liter Flows for Hypercapnic Patients?
Vapotherm’s Hi-VNI® Technology can be used to treat respiratory distress in hospital settings. Vapotherm does not practice medicine or provide medical services. These guidelines are based on an assessment of peer-reviewed published literature, physician interviews, and physiological modeling. Providers should refer to the full indications for use, operating instructions, and prescribing information of any products referenced herein before prescribing them.
New Randomized Controlled Trial Recommends Vapotherm High Velocity Therapy as Front-Line Tool for Patients Admitted to ICU with Severe Bronchiolitis
In June 2018, Ergul and colleagues published the results of a single-center, randomized controlled trial in the European Journal of Pediatrics titled “Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study.”
Study Suggests Sedation May Prevent NIV Failure, but Continuous Sedation May Increase Mortality in DNI Patients
In July 2015, Matsumoto and colleagues published the results of a retrospective, single-center study in BMC Pulmonary Medicine titled “Role of sedation for agitated patients undergoing noninvasive ventilation: clinical practice in a tertiary referral hospital.” The study examined records of 3506 consecutive patients that had been placed on noninvasive ventilation (NIV).